RU2350333C3 - Применение ивермектина для лечения дерматологических расстройств - Google Patents

Применение ивермектина для лечения дерматологических расстройств

Info

Publication number
RU2350333C3
RU2350333C3 RU2005136438A RU2005136438A RU2350333C3 RU 2350333 C3 RU2350333 C3 RU 2350333C3 RU 2005136438 A RU2005136438 A RU 2005136438A RU 2005136438 A RU2005136438 A RU 2005136438A RU 2350333 C3 RU2350333 C3 RU 2350333C3
Authority
RU
Russia
Prior art keywords
treatment
ivermectin
application
dermatologic disorders
composition
Prior art date
Application number
RU2005136438A
Other languages
English (en)
Russian (ru)
Other versions
RU2005136438A (ru
RU2350333C2 (ru
Original Assignee
Галдерма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2350333(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Галдерма С.А. filed Critical Галдерма С.А.
Publication of RU2005136438A publication Critical patent/RU2005136438A/ru
Application granted granted Critical
Publication of RU2350333C2 publication Critical patent/RU2350333C2/ru
Publication of RU2350333C3 publication Critical patent/RU2350333C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
RU2005136438A 2003-04-24 2004-04-22 Применение ивермектина для лечения дерматологических расстройств RU2350333C3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0305048 2003-04-24
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
US60/468,994 2003-05-09

Publications (3)

Publication Number Publication Date
RU2005136438A RU2005136438A (ru) 2006-05-27
RU2350333C2 RU2350333C2 (ru) 2009-03-27
RU2350333C3 true RU2350333C3 (ru) 2018-08-24

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005136438A RU2350333C3 (ru) 2003-04-24 2004-04-22 Применение ивермектина для лечения дерматологических расстройств

Country Status (16)

Country Link
US (6) US7550440B2 (enExample)
EP (1) EP1620113B1 (enExample)
JP (2) JP5711867B2 (enExample)
KR (1) KR101187231B1 (enExample)
AU (1) AU2004231323C1 (enExample)
BR (1) BRPI0410503B8 (enExample)
CA (1) CA2522579C (enExample)
CY (2) CY1111797T1 (enExample)
FR (1) FR15C0069I2 (enExample)
HU (1) HUS1500048I1 (enExample)
LT (1) LTC1620113I2 (enExample)
LU (1) LU92915I2 (enExample)
MX (1) MXPA05011208A (enExample)
PL (2) PL1620113T3 (enExample)
RU (1) RU2350333C3 (enExample)
WO (1) WO2004093886A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
AU2003275509A1 (en) * 2003-05-25 2004-12-13 Eco Animal Health Ltd. Dimeticone-containing sustained formulation
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) * 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
US20100093652A1 (en) * 2006-10-12 2010-04-15 Topaz Pharmaceuticals Inc. Preservative System for Emulsion-Based Therapeutic Topical Formulations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
EP2091325B1 (en) * 2006-10-12 2014-08-06 Topaz Pharmaceuticals Inc. Shampoo-conditioner formulations comprising an avermectin for elimination of, and prophylaxis against, susceptible and treatment-resistant strains of lice
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
JP2012513387A (ja) * 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
KR102428738B1 (ko) 2013-08-08 2022-08-02 노반, 인크. 국소 조성물 및 그의 사용 방법
MX370957B (es) * 2013-11-29 2020-01-09 Galderma Sa Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica.
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US20170232024A1 (en) * 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2017064206A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a composition comprising a high concentration of one or more avermectins
US11154565B2 (en) * 2015-10-13 2021-10-26 Galderma Holding SA Process for preparing a stable emulsion comprising one or more avermectins
RU2738932C2 (ru) * 2016-08-04 2020-12-18 Нестле Скин Хелт Са Композиции и их применение для лечения или профилактики розацеа
WO2018060870A1 (en) * 2016-09-30 2018-04-05 Aurobindo Pharma Limited Pharmaceutical composition of ivermectin and process for preparation thereof
EP3534894A1 (en) 2016-11-03 2019-09-11 Nestlé Skin Health SA Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
PT3638251T (pt) * 2017-06-12 2024-05-22 Lakewood Amedex Inc Formulações de gel de bifosfocina e suas utilizações
CN111655241B (zh) 2017-12-15 2024-10-15 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
KR20210019449A (ko) 2018-06-15 2021-02-22 더블유.알. 그레이스 앤드 캄파니-콘. 소포 활성제, 이의 제조 방법, 및 소포 제형
EP3856145A1 (en) * 2018-09-28 2021-08-04 Galderma Research & Development Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
KR20220066068A (ko) * 2019-08-21 2022-05-23 팀버 파마슈티칼스, 인코포레이티드 활성 제제의 국소 전달을 위한 용매 전달 시스템
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
AU781703B2 (en) * 1999-01-25 2005-06-09 Blue Ridge Pharmaceuticals, Inc. Liposome formulations
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
AU2003215011A1 (en) * 2002-02-08 2003-09-02 Mcneil-Ppc, Inc. Topical ivermectin composition
CN1649578A (zh) * 2002-03-04 2005-08-03 戴弗根斯公司 杀线虫的脂肪酸和脂肪酸酯相关化合物
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme

Also Published As

Publication number Publication date
MXPA05011208A (es) 2005-12-14
JP2012126738A (ja) 2012-07-05
RU2005136438A (ru) 2006-05-27
PL378932A1 (pl) 2006-06-12
AU2004231323C1 (en) 2016-11-03
US20130209381A1 (en) 2013-08-15
BRPI0410503A (pt) 2006-06-20
US8080530B2 (en) 2011-12-20
JP5538461B2 (ja) 2014-07-02
LTC1620113I2 (lt) 2018-02-26
WO2004093886A1 (en) 2004-11-04
US20120258062A1 (en) 2012-10-11
JP5711867B2 (ja) 2015-05-07
US8598129B2 (en) 2013-12-03
EP1620113B1 (en) 2011-07-13
CA2522579A1 (en) 2004-11-04
CA2522579C (en) 2012-08-28
US8470788B2 (en) 2013-06-25
US8415311B2 (en) 2013-04-09
AU2004231323B2 (en) 2009-12-10
US20090252797A1 (en) 2009-10-08
FR15C0069I1 (enExample) 2015-12-04
HUS1500048I1 (hu) 2017-10-30
KR20060004667A (ko) 2006-01-12
BRPI0410503B1 (pt) 2018-07-10
AU2004231323A1 (en) 2004-11-04
CY2016031I2 (el) 2017-03-15
US20120077766A1 (en) 2012-03-29
CY2016031I1 (el) 2017-03-15
EP1620113A1 (en) 2006-02-01
RU2350333C2 (ru) 2009-03-27
JP2006524212A (ja) 2006-10-26
US7550440B2 (en) 2009-06-23
US8093219B2 (en) 2012-01-10
PL1620113T3 (pl) 2011-10-31
US20090227668A1 (en) 2009-09-10
BRPI0410503B8 (pt) 2021-05-25
FR15C0069I2 (fr) 2016-04-22
CY1111797T1 (el) 2015-10-07
LU92915I2 (fr) 2016-02-17
US20060100165A1 (en) 2006-05-11
KR101187231B1 (ko) 2012-10-02

Similar Documents

Publication Publication Date Title
RU2350333C3 (ru) Применение ивермектина для лечения дерматологических расстройств
BRPI0309544B8 (pt) preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
EA200600484A1 (ru) Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды
FR2866884B1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2889811B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
JP2007536277A5 (enExample)
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
JP2005507892A5 (enExample)
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
ECSP077843A (es) Tratamiento o prevención del prurito
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
BRPI0418764B8 (pt) uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano
FR2873693B1 (fr) Derives d'amino-tropane, leur preparation et leur application en therapeutique
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
WO2001080891A8 (en) Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
EA200702496A1 (ru) Местная композиция, содержащая желатин
BRPI0607976A2 (pt) composição farmacêutica e uso de uma composição
FR2866886B1 (fr) Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
JP2010521519A5 (enExample)
JP2004224775A5 (enExample)
ITMI20041871A1 (it) Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce
ITBO20020022A1 (it) Composizioni farmaceutiche per la cura della pelle e il loro impiego
de Hoon et al. Lack of significant pharmacodynamic interaction between telcagepant 600 mg and sumatriptan 100 mg: PO08

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20180824